

## S 1062

### FDA Reporting Transparency and Accountability Act

**Congress:** 115 (2017–2019, Ended)

**Chamber:** Senate

**Policy Area:** Health

**Introduced:** May 4, 2017

**Current Status:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

**Latest Action:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (May 4, 2017)

**Official Text:** <https://www.congress.gov/bill/115th-congress/senate-bill/1062>

### Sponsor

**Name:** Sen. Burr, Richard [R-NC]

**Party:** Republican • **State:** NC • **Chamber:** Senate

### Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Young, Todd [R-IN]	R · IN		May 4, 2017

### Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	May 4, 2017

### Subjects & Policy Tags

#### Policy Area:

Health

### Related Bills

Bill	Relationship	Last Action
115 HR 2430	Related bill	<b>Aug 18, 2017:</b> Became Public Law No: 115-52.
115 S 934	Related bill	<b>May 11, 2017:</b> Placed on Senate Legislative Calendar under General Orders. Calendar No. 76.

### Summary (as of May 4, 2017)

### FDA Reporting Transparency and Accountability Act

This bill expands reporting requirements related to the performance of the Food and Drug Administration (FDA), including to require additional information on timeliness and personnel and publication every 30 days of information regarding FDA guidance and meetings.

### Actions Timeline

- **May 4, 2017:** Introduced in Senate
- **May 4, 2017:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.